Cytek Biosciences, Inc.
NasdaqGS:CTKB Rapporto sulle azioni
Cap. di mercato: US$906.8m
Cytek Biosciences Salute del bilancio
Salute finanziaria criteri di controllo 5/6 Cytek Biosciences ha un patrimonio netto totale di $385.5M e un debito totale di $3.2M, che porta il suo rapporto debito/patrimonio netto a 0.8%. Le sue attività totali e le sue passività totali sono rispettivamente $491.2M e $105.8M.
Informazioni chiave
0.8%
Rapporto debito/patrimonio netto
Indice di copertura degli interessi n/a Contanti US$277.78m Patrimonio netto US$385.46m Totale passività US$105.76m Totale attività US$491.23m
Aggiornamenti recenti sulla salute finanziaria
Mostra tutti gli aggiornamenti
Cytek Biosciences, Inc. Introduces an Enhanced Small Particle Detection Option for Its Cytek Aurora Cs System Nov 08
Investors Still Aren't Entirely Convinced By Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Revenues Despite 46% Price Jump Nov 07
New minor risk - Share price stability Nov 06
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Nov 06
Cytek Biosciences, Inc. Reaffirms Earnings Guidance for the Year 2024 Nov 06
Cytek Biosciences, Inc. to Report Q3, 2024 Results on Nov 05, 2024 Oct 30
Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Shares Not Telling The Full Story Sep 13
Cytek Biosciences, Inc. Announces Resignation of Paul Christopher Williams as Chief Operating Officer, Effective September 27, 2024 Sep 12
Price target decreased by 8.4% to US$8.70 Aug 16
Consensus EPS estimates fall by 90% Aug 15
Consensus EPS estimates fall by 52% Aug 13
An Intrinsic Calculation For Cytek Biosciences, Inc. (NASDAQ:CTKB) Suggests It's 49% Undervalued Aug 09
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Aug 07 Cytek Biosciences, Inc. Narrows Earnings Guidance for the Year 2024 Aug 07
Cytek Biosciences, Inc. Automates Panel Design with New Intelligent Algorithm
Consensus EPS estimates fall by 15% Jul 23
Is Cytek Biosciences (NASDAQ:CTKB) Using Debt Sensibly? Jul 12 Cytek Biosciences, Inc. (NasdaqGS:CTKB) announces an Equity Buyback for $50 million worth of its shares. Jun 08
Potential Upside For Cytek Biosciences, Inc. (NASDAQ:CTKB) Not Without Risk Jun 04
Cytek Biosciences, Inc. Reaffirms Earnings Guidance for the Year Ending December 31, 2024 May 10
Cytek Biosciences, Inc. to Report Q1, 2024 Results on May 08, 2024 May 01
Cytek Biosciences, Inc., Annual General Meeting, Jun 05, 2024 Apr 28
Cytek Biosciences: Undisputed Next-Gen Flow Cytometry Leader Mar 20 Cytek Biosciences, Inc. Announces CFO Changes Cytek Biosciences, Inc. announced delayed annual 10-K filing Mar 03
Cytek Biosciences, Inc. Provides Earnings Guidance for the Year Ended December 31, 2024 Mar 01
Full year 2023 earnings released Feb 29
Cytek Biosciences, Inc. to Report Q4, 2023 Results on Feb 28, 2024 Feb 08
Cytek Biosciences, Inc. Provides Revenue Guidance for the Year 2023 Jan 08
Cytek Biosciences Introduces the Cytek Orion™ Reagent Cocktail Preparation System, the First-of-its-Kind Automated Cocktail Preparation Instrument for Flow Cytometry Dec 21
Cytek Biosciences, Inc. announced delayed 10-Q filing Nov 15 Cytek Biosciences, Inc. announced delayed 10-Q filing Nov 14
Third quarter 2023 earnings: EPS and revenues miss analyst expectations Nov 10
Cytek Biosciences, Inc. Provides Revenue Guidance for the Year 2023 Nov 08
CTO & Director notifies of intention to sell stock Oct 22
Cytek Biosciences, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Oct 20
Price target decreased by 14% to US$12.25 Oct 18
President notifies of intention to sell stock Sep 10
Cytek Biosciences Appoints Dr. Philippe Busque Senior Vice President of Global Sales & Services Aug 29
CTO & Director notifies of intention to sell stock Aug 24
Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 09
Cytek Biosciences, Inc. Provides Revenue Guidance for the Full Year 2023 Aug 09
Cytek Biosciences, Inc. to Report Q2, 2023 Results on Aug 08, 2023 Jul 23
CTO & Director notifies of intention to sell stock Jun 25
President notifies of intention to sell stock Jun 11
Cytek Biosciences, Inc. (NasdaqGS:CTKB) announces an Equity Buyback for $50 million worth of its shares. May 20
President notifies of intention to sell stock May 12
First quarter 2023 earnings: EPS and revenues miss analyst expectations May 11
Cytek Biosciences, Inc. Revises Earnings Guidance for the Year 2023 May 10
CTO & Director notifies of intention to sell stock Apr 23
Consensus EPS estimates increase by 22% Apr 19
Cytek Biosciences' (NASDAQ:CTKB) Solid Profits Have Weak Fundamentals Mar 08
Price target decreased by 9.1% to US$15.00 Mar 07
Full year 2022 earnings: EPS and revenues miss analyst expectations Mar 02
Cytek Biosciences, Inc. (NasdaqGS:CTKB) entered into an agreement to acquire Flow Cytometry & Imaging (FCI) business unit of Luminex Corporation for $46.5 million. Feb 14
President notifies of intention to sell stock Feb 12
Cytek Biosciences, Inc. to Report Q4, 2022 Results on Feb 28, 2023 Feb 08
CTO & Director notifies of intention to sell stock Jan 23
President notifies of intention to sell stock Dec 11
Chief Financial Officer notifies of intention to sell stock Dec 02
CTO & Director notifies of intention to sell stock Nov 25
Lead Independent Director exercised options and sold US$229k worth of stock Nov 17
Cytek Biosciences, Inc. Introduces Cytek Cloud Nov 16
Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 10
Cytek Biosciences, Inc. Provides Revenue Guidance for the Year 2022 Nov 10
Cytek Biosciences, Inc. Names Chris Williams Chief Operating Officer Nov 01
Cytek Biosciences, Inc. to Report Q3, 2022 Results on Nov 09, 2022 Oct 27
President notifies of intention to sell stock Sep 11
CTO & Director notifies of intention to sell stock Aug 25
Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 12
Cytek Biosciences, Inc. Provides Earnings Guidance for the Full Year 2022 Aug 11
Chief Financial Officer notifies of intention to sell stock Aug 05
Cytek Biosciences Vs. 10x Genomics: 2 Opposing Cell Visualization Investments Jul 27
Cytek Biosciences, Inc. to Report Q2, 2022 Results on Aug 10, 2022 Jul 21
Cytek Biosciences, Inc.(NasdaqGS:CTKB) dropped from Russell 2500 Value Index Jun 26
Cytek Biosciences, Inc. Reaffirms Earning Guidance for 2022 Jun 24
Cytek Biosciences, Inc. Elects Deborah Neff, Don Hardison as Class I Director Jun 07
CTO & Director notifies of intention to sell stock May 23
President notifies of intention to sell stock May 13
Cytek Biosciences, Inc. Provides Revenue Guidance for the Full Year 2022 May 12
Cytek Biosciences, Inc., Annual General Meeting, Jun 01, 2022 Apr 15
Consensus forecasts updated Apr 14
Checking In On Cytek Biosciences Mar 23
President exercised options and sold US$248k worth of stock Mar 10
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 01
Cytek Biosciences, Inc. Provides Revenue Guidance for the Fiscal Year 2022 Feb 24
CTO & Director notifies of intention to sell stock Feb 14
Cytek Biosciences, Inc. to Report Q4, 2021 Results on Feb 23, 2022 Feb 12
Cytek Biosciences, Inc. has completed an IPO in the amount of $247.598795 million. Jul 24
Analisi della posizione finanziaria
Passività a breve termine: Le attività a breve termine ( $390.2M ) di CTKB superano le sue passività a breve termine ( $62.8M ).
Passività a lungo termine: Le attività a breve termine di CTKB ( $390.2M ) superano le sue passività a lungo termine ( $43.0M ).
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: CTKB ha più liquidità del suo debito totale.
Riduzione del debito: Dati insufficienti per determinare se il rapporto debito/patrimonio netto di CTKB si sia ridotto negli ultimi 5 anni.
Analisi della pista di contanti Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.
Pista di liquidità stabile: Sebbene non redditizia CTKB ha una pista di cassa sufficiente per più di 3 anni se mantiene il suo attuale livello positivo di flusso di cassa libero .
Previsione Cash Runway: CTKB non è redditizia ma ha una liquidità sufficiente per più di 3 anni, grazie al flusso di cassa libero positivo e in crescita del 8.5 % all'anno.
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
